Vinay Prasad regained additional FDA titles as Chief Medical and Scientific Officer shortly after his return as director of the Center for Biologics Evaluation and Research. The FDA's top drug regulator denied reports that the agency plans to 'abandon' advisory committee meetings. Regulatory updates continue with new drug designations, clinical trial authorizations, and actions impacting market access and drug development pipelines, reflecting an active oversight environment in biopharma innovation and safety.